Sanofi (NASDAQ:SNY) Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. lowered its stake in Sanofi (NASDAQ:SNY - Free Report) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 143,510 shares of the company's stock after selling 8,896 shares during the quarter. QRG Capital Management Inc.'s holdings in Sanofi were worth $6,921,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Oppenheimer Asset Management Inc. boosted its position in shares of Sanofi by 1.0% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 126,811 shares of the company's stock worth $6,116,000 after buying an additional 1,216 shares during the period. NewEdge Wealth LLC lifted its stake in Sanofi by 20.5% during the 4th quarter. NewEdge Wealth LLC now owns 32,799 shares of the company's stock worth $1,582,000 after acquiring an additional 5,591 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Sanofi during the 4th quarter valued at about $76,000. Argonautica Private Wealth Management Inc. grew its position in Sanofi by 16.6% in the 4th quarter. Argonautica Private Wealth Management Inc. now owns 6,481 shares of the company's stock valued at $313,000 after acquiring an additional 925 shares in the last quarter. Finally, Lake Street Advisors Group LLC increased its stake in Sanofi by 6.0% during the fourth quarter. Lake Street Advisors Group LLC now owns 7,121 shares of the company's stock worth $343,000 after purchasing an additional 406 shares during the period. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $60.00.

Sanofi Stock Up 4.0 %

Shares of SNY traded up $2.20 during midday trading on Monday, hitting $56.67. The company had a trading volume of 1,122,745 shares, compared to its average volume of 2,354,189. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The firm has a market capitalization of $143.81 billion, a P/E ratio of 22.73, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company's 50-day simple moving average is $51.65 and its 200-day simple moving average is $52.59.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.